Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 2,250 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.90, for a total value of $137,025.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at approximately $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00.
• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.67, for a total value of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.

Vaxcyte Stock Down 5.7%

NASDAQ:PCVX opened at $61.92 on Friday. Vaxcyte, Inc. has a fifty-two week low of $40.14 and a fifty-two week high of $90.75. The firm’s fifty day simple moving average is $61.65 and its 200-day simple moving average is $57.23.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter in the previous year, the company posted ($1.56) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -7.47 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on PCVX. BTIG Research reaffirmed a “buy” rating and issued a $89.00 target price on shares of Vaxcyte in a report on Monday, October 5th. Guggenheim lifted their price target on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $120.00 price target on shares of Vaxcyte in a report on Monday, October 12th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PCVX. Jupiter Topco LLC purchased a new position in Vaxcyte during the second quarter worth $1,044,355,000. BlackRock Inc. acquired a new position in shares of Vaxcyte in the second quarter worth $701,520,000. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after acquiring an additional 3,188,687 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock worth $407,001,000 after acquiring an additional 1,386,968 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Vaxcyte during the second quarter valued at $62,711,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.